Lifeboat Foundation

Ball is not alone in calling for a drastic rethink of how scientists discuss biology. There has been a flurry of publications in this vein in the past year, written by me and others^2–4. All outline reasons to redefine what genes do. All highlight the physiological processes by which organisms control their genomes. And all argue that agency and purpose are definitive characteristics of life that have been overlooked in conventional, gene-centric views of biology.

This burst of activity represents a frustrated thought that “it is time to become impatient with the old view”, as Ball says. Genetics alone cannot help us to understand and treat many of the diseases that cause the biggest health-care burdens, such as schizophrenia, cardiovascular diseases and cancer. These conditions are physiological at their core, the author points out — despite having genetic components, they are nonetheless caused by cellular processes going awry. Those holistic processes are what we must understand, if we are to find cures.

Ultimately, Ball concludes that “we are at the beginning of a profound rethinking of how life works”. In my view, beginning is the key word here. Scientists must take care not to substitute an old set of dogmas with a new one. It’s time to stop pretending that, give or take a few bits and pieces, we know how life works. Instead, we must let our ideas evolve as more discoveries are made in the coming decades. Sitting in uncertainty, while working to make those discoveries, will be biology’s great task for the twenty-first century.

Photonic integrated circuits are an important next-wave technology. These sophisticated microchips hold the potential to substantially decrease costs and increase speed and efficiency for electronic devices across a wide range of application areas, including automotive technology, communications, health care, data storage, and computing for artificial intelligence.

Photonic circuits use photons, fundamental particles of light, to move, store, and access information in much the same way that conventional electronic circuits use electrons for this purpose. Photonic chips are already in use today in advanced fiber-optic communication systems, and they are being developed for implementation in a broad spectrum of near-future technologies, including light detection and ranging, or LiDAR, for autonomous vehicles; light-based sensors for medical devices; 5G and 6G communication networks; and optical and quantum computing.

Given the broad range of existing and future uses for photonic integrated circuits, access to equipment that can fabricate chip designs for study, research and industrial applications is also important. However, today’s nanofabrication facilities cost millions of dollars to construct and are well beyond the reach of many colleges, universities, and research labs.

Washington state is experiencing its first known outbreak of a potentially deadly fungus, according to public health officials.

Four patients in the last month have tested positive for Candida auris, or C. auris, Public Health — Seattle & King County said in a release.

The first case occurred in a patient who had recently been admitted to Kindred Hospital Seattle, which was identified through a proactive screening program.

SpaceX will become the co-owner of valuable data, biological samples, and possibly even patents and intellectual property related to human spaceflight, according to the terms and conditions of a new program inviting research on crewed Dragon missions.

The company started quietly inviting proposals “for exceptional science and research ideas that will enable life in space and on other planets,” to be executed on orbit using its Dragon spacecraft capsule. Specifically, SpaceX says it’s looking for research studies and experiments focused on fitness, or solutions to increase “efficiency and effectiveness,” and those focused on human health during long-duration spaceflight missions.

Selected research study groups would have access to SpaceX’s crewed Dragon missions, opening up a whole new use case for one of the company’s core products.

A team of molecular engineers have developed a type of plastic that can be shape-shifted using tempering. In their paper published in the journal Science the team, from the University of Chicago, with a colleagues from the US DEVCOM Army Research Laboratory, Aberdeen Proving Ground, the National Institutes of Standards and Technology and the NASA Glenn Research Center, describe how they made their plastic and how well it was able to shape shift when they applied various types of tempering.

Haley McAllister and Julia Kalow, with Northwestern University, have published a Perspective piece in the same issue of Science outlining the work.

Over the past several years, it has become evident that the use of plastics in products is harmful to not only the environment but also human health —bits of plastic have been found in the soil, the atmosphere, the oceans, and the human body.

A gene editing tool using a system known as CRISPR-Cas9 has recently been approved by the U.S. Food and Drug Administration (FDA) for sickle cell disease. The drug is known as Casgevy and the media has hailed this treatment as a ‘cure’ for sickle cell anemia patients. While it is still unclear if the drug completely cures these patients, clinical trials show exciting efficacy.

Sickle cell disease is a genetic blood disorder affecting thousands of US citizens. Many of these patients are African American and Hispanic. In sickle cell disease, hemoglobin, a protein in red blood cells that helps carry oxygen throughout the body, is mutated. As a result, blood cells change shape in the form of a sickle, giving the disease its name. Unfortunately, the mutated cells cause disruption of blood flow and prevent other blood cells from delivering oxygen to the body. This disease is extremely rare and can lower the quality of life in patients. Previously, there were limited treatments options including transfusions and medications for pain management. However, Casgevy provides a new option to help treat the patient and relieve pain for over a year after a single treatment.

One-time treatment using Casgevy improved life quality for sickle cell patients. A single-arm trial was conducted at multiple health centers in adults and adolescents. These patients were screened for two vaso-occlusive crises (VOCs) which are described as severely painful events due to a lack of oxygen delivery from sickle cell blood cells blocking blood flow. The primary measure of success in the trial was the number of VOCs after treatment. In total, 44 patients received Casgevy and 33 were able to follow up and be evaluated. Of the 33 patients that made it through the trial, 29 of them did not experience any VOCs for 12 months. This is a 93.5% success rate based on the number of patients that were analyzed. All 44 patients were able to successfully undergo treatment without any graft rejection. In addition, researchers concluded that this treatment was not only effective, but safe with few side effects.

Our very old immune systems can’t keep up with modern lifestyles and diets, leading to increases in all sorts of chronic health problems like allergies and obesity.

Hybrid Intelligence, an emerging field at the intersection of human intellect and artificial intelligence (AI), is redefining the boundaries of what can be achieved when humans and machines collaborate. This synergy leverages the creativity and emotional intelligence of humans with the computational power and efficiency of machines. Let’s explore how hybrid intelligence is augmenting human capabilities, with real examples and its impacts on the human workforce.

Hybrid intelligence is not just about AI assisting humans; it’s a deeper integration where both sets of intelligence complement each other’s strengths and weaknesses. While AI excels in processing vast amounts of data and pattern recognition, it lacks the emotional intelligence, creativity, and moral reasoning humans possess. Hybrid systems are designed to capitalize on these respective strengths, leading to outcomes that neither could achieve alone.

In the healthcare sector, hybrid intelligence is enhancing diagnostic accuracy and treatment efficiency. IBM’s Watson Health, for example, assists doctors in diagnosing and developing treatment plans for cancer patients. By analyzing medical literature and patient data, Watson provides recommendations based on the latest research, which doctors then evaluate and contextualize based on their professional judgment and patient interaction.

In today’s column, I am continuing my ongoing series about the impact of generative AI in the health and medical realm.

You can use generative AI to analyze your sleeping dreams, but do so with caution and a keen eye. This close up look tells you how to best proceed.